Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego — Clinical Trial Site

40 Registered trials

20 Currently recruiting

Organisation

Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego

Location

Walbrzych, Poland

Identifier

ORG-100044518

Address

Ul. Alfreda Sokolowskiego 4, 58-309, Poland

Departments

2101: Oddzial Hematologii
2800 : Oddział Hematologiczny
Cardiology
Hematology
N/A
NA
Nephrology
Oddzial Hematologiczny
Oddzial Hematologii
Oddzial Kardiologiczny
Oddział Hematologiczny
Oddział Hematologii
Oddział Hematologiczny
ODDZIAŁ HEMATOLOGII
Oddział Kardiologii
Oddział Onkologiczny - Centrum Kompetencji Raka Piersi, Centrum Kompetencji Raka Jelita Grubego
Oncology

Clinical trials at this site (40)

Search interface

A Phase 3b Study of BMS-986346 in Lower-risk Myelodysplastic Syndrome Participants Ended

2023-504541-31-00 Myelodysplastic syndrome 5 2024-03-06
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A phase 1/2 study of SLN124 in patients with Polycythemia Vera Ended

2023-503544-13-00 Polycythemia Vera 9 2023-11-02
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Myelodysplastic Syndrome (MDS) 5 2023-10-11
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended

2024-510800-35-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-06-17
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended

2023-503441-55-00 Relapsed/Refractory Multiple Myeloma 4 2021-10-14
A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended

2023-507890-17-00 Anemia associated with myeloproliferative neoplasm (MPN 5 2021-02-22
Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended

2023-509908-15-00 Mantle Cell Lymphoma 10 2020-01-20
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended

2022-501485-22-00 Myelodysplastic syndrome (MDS) 5 2018-12-18
Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study Halted

2024-518951-52-00 Worsening Heart Failure 4 2025-11-12
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo… Ended

2023-505910-10-00 Relapsed or Refractory High-Risk Myelodysplastic Syndro 4 2024-01-23
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
Phase 2 Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial I… Ended

2023-507569-24-00 Myocardial Infarction, Acute Heart Failure, Left Sided 4 2022-06-20
A Study of the Efficacy and Safety of MK-5475 in Participants with Pulmonary Arterial Hypertension Ended

2022-500877-15-00 Pulmonary arterial hypertension (PAH) in one of the fol 10 2021-06-25
Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended

2023-510361-97-00 Newly Diagnosed RARA-positive Adult Patients with Highe 5